DOI: 10.3748/wjg.v12.i43.6973. Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone

Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone

10.3748/wjg.v12.i43.6973

Crossref journal-article

Baishideng Publishing Group Inc.

World Journal of Gastroenterology (2060)

Bibliography

Xie, D.-R. (2006). Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone. World Journal of Gastroenterology, 12(43), 6973.

Authors 1

De-Rong Xie (first)

References 32 Referenced 31

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413. (10.1200/JCO.1997.15.6.2403)
10.1016/0197-2456(95)00134-4
10.1136/bmj.320.7249.1574
Degen G, Hong Z. Treatment effectiveness evaluation of gemcitabine for pancreatic cancer. Zhonghua Fubu Jibing Zazhi 2003;3:570-571.
Ohkawa S. Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2004;22:4131. (10.1200/jco.2004.22.14_suppl.4131)
Richards DA, Oettle H, Vervenne WL, Saif MW, Thomas JP, Spitzer G, Visseren-Grul C, Enas N and Weitzman A. Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs GEM plus placebo in advanced adenocarcinoma of the pancreas. J Clin Oncol 2005;23:4092. (10.1200/jco.2005.23.16_suppl.4092)
Shapiro J, Marshall J, Karasek P, Figer A, Oettle H, Couture F, Jeziorski K, Broome P and Hawkins R. G17DT gemcitabine [Gem] versus placebo Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 2005;23:4012. (10.1200/jco.2005.23.16_suppl.lba4012)
10.1093/annonc/mdg029
10.1002/cncr.10323
Wang XY, Ni QX, Jin ML, Li ZS, Wu YX, Zhao YP and Feng FY. Gemcitabine or gemcitabine plus cisplatin for in patients with locally advanced or metastatic pancreatic cancer. Zhonghua Fubu Jibing Zazhi 2002;24:404-407.
10.1007/s00423-001-0267-5
10.1200/JCO.2002.11.149
10.1038/sj.bjc.6600446
10.1200/JCO.2004.10.112
10.1200/JCO.2005.06.023
O'Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano M, Hurwitz H, Tchekmedyian NS, Ackerman J, De Jager RL and Eckhardt SG. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2004;22:4006.
Richards DA, Oettle H, Ramanathan R, Ramanathan RK, Van Laethem J-L, Peeters M, Fuchs M, John W, Arning M and Von Hoff D. A randomized phase III study comparing gemcitabine pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004;22:4007. (10.1200/jco.2004.22.14_suppl.4007)
Li CP, Chao Y. A prospective randomized trial of gemcitabine alone or gemcitabine cisplatin in the treatment of metastatic pancreatic cancer. J Clin Oncol 2004;22:4144. (10.1200/jco.2004.22.14_suppl.4144)
Reni M, Cordio S, Passardi A, Panucci MG, Passoni P, Oliani C, Luppi G, Galli L, Nicoletti R and Villa E. Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA). J Clin Oncol 2004;22:4010. (10.1200/jco.2004.22.14_suppl.4010)
Viret F, Ychou M, Lepille D, Mineur L, Navarro F, Topart D, Fonck M, Goineau J, Madroszyk-Flandin A and Chouaki N. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. J Clin Oncol 2004;22:4118. (10.1200/jco.2004.22.14_suppl.4118)
Rocha Lima CMS, Rotche R, Jeffery M, Trudeau M, Cisar L A, Morganti A, Gruia G, Miller L and Green MR. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 2003;22:1005.
Di Costanzo F, Sdrobolini A, Carlini P, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P and Ospedaliera S A. Gemcitabine (GEM) Alone or in Combination with 5-FU Continuous Infusion (CI) in the Treatment of Advanced Pancreatic Cancer (APC): a GOIRC Randomized Phase II Trial. Proc Am Soc Clin Oncol 2001;20:612.
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Stoffregen C and Clemens M. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2003;22:1003.
Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR and Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). J Clin Oncol 2004;22:4011. (10.1200/jco.2004.22.14_suppl.4011)
Richards DA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Dasse KD, Macdonald K, Gulyas S, Plante M, Copley-Merriman C and Grove W. Randomized, double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994 G) versus placebo plus gemcitabine (P G) in the treatment of patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2002;21:644.
Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, Nomikos D, Ding K, Ptaszynski M, Parulekar W. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. 2005 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to Gastrointestinal Malignancies and Premalignancies; 2005 January 27-29; Hollywood, FL: Abstract 77 .
Stathopoulos G, Aravantinos G, Syrigos K, Kalbakis K, Karvounis N, Papakotoulas P, Boukovinas J, Potamianou A, Polyzos A, Christophillakis C and Georgoulias V. A randomized phase III study of irinotecan/ gemcitabine combination versus gemcitabine in patients with advanced/ metastatic pancreatic cancer. J Clin Oncol 2005;23:4106. (10.1200/jco.2005.23.16_suppl.4106)
Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K, Weigang-Köhler K, Stauch M and Oettle H. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:4009. (10.1200/jco.2005.23.16_suppl.lba4009)
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, Schueller J, Bernhard J, Dietrich D and Scheithauer W. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005;23:4010. (10.1200/jco.2005.23.16_suppl.lba4010)
Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997;24:S7-8-S7-16.
Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-530.
10.1111/j.1443-9573.2006.00244.x

Dates

Type	When
Created	9 years, 5 months ago (March 15, 2016, 11:53 p.m.)
Deposited	6 years ago (Sept. 5, 2019, 7:49 a.m.)
Indexed	9 months, 2 weeks ago (Nov. 19, 2024, 12:06 p.m.)
Issued	19 years, 8 months ago (Jan. 1, 2006)
Published	19 years, 8 months ago (Jan. 1, 2006)
Published Print	19 years, 8 months ago (Jan. 1, 2006)

Funders 0

None

BibTeX

@article{Xie_2006, title={Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone}, volume={12}, ISSN={1007-9327}, url={http://dx.doi.org/10.3748/wjg.v12.i43.6973}, DOI={10.3748/wjg.v12.i43.6973}, number={43}, journal={World Journal of Gastroenterology}, publisher={Baishideng Publishing Group Inc.}, author={Xie, De-Rong}, year={2006}, pages={6973} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2024,
        11,
        19
      ]
    ],
    "date-time": "2024-11-19T17:06:14Z",
    "timestamp": 1732035974866
  },
  "reference-count": 32,
  "publisher": "Baishideng Publishing Group Inc.",
  "issue": "43",
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2006
      ]
    ]
  },
  "DOI": "10.3748/wjg.v12.i43.6973",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2016,
        3,
        16
      ]
    ],
    "date-time": "2016-03-16T03:53:08Z",
    "timestamp": 1458100388000
  },
  "page": "6973",
  "source": "Crossref",
  "is-referenced-by-count": 31,
  "title": "Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone",
  "prefix": "10.3748",
  "volume": "12",
  "author": [
    {
      "given": "De-Rong",
      "family": "Xie",
      "sequence": "first",
      "affiliation": []
    }
  ],
  "member": "2060",
  "reference": [
    {
      "key": "ref1",
      "doi-asserted-by": "crossref",
      "unstructured": "Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.",
      "DOI": "10.1200/JCO.1997.15.6.2403"
    },
    {
      "key": "ref2",
      "doi-asserted-by": "publisher",
      "DOI": "10.1016/0197-2456(95)00134-4"
    },
    {
      "key": "ref3",
      "doi-asserted-by": "publisher",
      "DOI": "10.1136/bmj.320.7249.1574"
    },
    {
      "key": "ref4",
      "unstructured": "Degen G, Hong Z. Treatment effectiveness evaluation of gemcitabine for pancreatic cancer. Zhonghua Fubu Jibing Zazhi 2003;3:570-571."
    },
    {
      "key": "ref5",
      "doi-asserted-by": "crossref",
      "unstructured": "Ohkawa S. Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2004;22:4131.",
      "DOI": "10.1200/jco.2004.22.14_suppl.4131"
    },
    {
      "key": "ref6",
      "doi-asserted-by": "crossref",
      "unstructured": "Richards DA, Oettle H, Vervenne WL, Saif MW, Thomas JP, Spitzer G, Visseren-Grul C, Enas N and Weitzman A. Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs GEM plus placebo in advanced adenocarcinoma of the pancreas. J Clin Oncol 2005;23:4092.",
      "DOI": "10.1200/jco.2005.23.16_suppl.4092"
    },
    {
      "key": "ref7",
      "doi-asserted-by": "crossref",
      "unstructured": "Shapiro J, Marshall J, Karasek P, Figer A, Oettle H, Couture F, Jeziorski K, Broome P and Hawkins R. G17DT gemcitabine [Gem] versus placebo Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 2005;23:4012.",
      "DOI": "10.1200/jco.2005.23.16_suppl.lba4012"
    },
    {
      "key": "ref8",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/annonc/mdg029"
    },
    {
      "key": "ref9",
      "doi-asserted-by": "publisher",
      "DOI": "10.1002/cncr.10323"
    },
    {
      "key": "ref10",
      "unstructured": "Wang XY, Ni QX, Jin ML, Li ZS, Wu YX, Zhao YP and Feng FY. Gemcitabine or gemcitabine plus cisplatin for in patients with locally advanced or metastatic pancreatic cancer. Zhonghua Fubu Jibing Zazhi 2002;24:404-407."
    },
    {
      "key": "ref11",
      "doi-asserted-by": "publisher",
      "DOI": "10.1007/s00423-001-0267-5"
    },
    {
      "key": "ref12",
      "doi-asserted-by": "publisher",
      "DOI": "10.1200/JCO.2002.11.149"
    },
    {
      "key": "ref13",
      "doi-asserted-by": "publisher",
      "DOI": "10.1038/sj.bjc.6600446"
    },
    {
      "key": "ref14",
      "doi-asserted-by": "publisher",
      "DOI": "10.1200/JCO.2004.10.112"
    },
    {
      "key": "ref15",
      "doi-asserted-by": "publisher",
      "DOI": "10.1200/JCO.2005.06.023"
    },
    {
      "key": "ref16",
      "unstructured": "O'Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano M, Hurwitz H, Tchekmedyian NS, Ackerman J, De Jager RL and Eckhardt SG. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2004;22:4006."
    },
    {
      "key": "ref17",
      "doi-asserted-by": "crossref",
      "unstructured": "Richards DA, Oettle H, Ramanathan R, Ramanathan RK, Van Laethem J-L, Peeters M, Fuchs M, John W, Arning M and Von Hoff D. A randomized phase III study comparing gemcitabine pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004;22:4007.",
      "DOI": "10.1200/jco.2004.22.14_suppl.4007"
    },
    {
      "key": "ref18",
      "doi-asserted-by": "crossref",
      "unstructured": "Li CP, Chao Y. A prospective randomized trial of gemcitabine alone or gemcitabine cisplatin in the treatment of metastatic pancreatic cancer. J Clin Oncol 2004;22:4144.",
      "DOI": "10.1200/jco.2004.22.14_suppl.4144"
    },
    {
      "key": "ref19",
      "doi-asserted-by": "crossref",
      "unstructured": "Reni M, Cordio S, Passardi A, Panucci MG, Passoni P, Oliani C, Luppi G, Galli L, Nicoletti R and Villa E. Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA). J Clin Oncol 2004;22:4010.",
      "DOI": "10.1200/jco.2004.22.14_suppl.4010"
    },
    {
      "key": "ref20",
      "doi-asserted-by": "crossref",
      "unstructured": "Viret F, Ychou M, Lepille D, Mineur L, Navarro F, Topart D, Fonck M, Goineau J, Madroszyk-Flandin A and Chouaki N. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. J Clin Oncol 2004;22:4118.",
      "DOI": "10.1200/jco.2004.22.14_suppl.4118"
    },
    {
      "key": "ref21",
      "unstructured": "Rocha Lima CMS, Rotche R, Jeffery M, Trudeau M, Cisar L A, Morganti A, Gruia G, Miller L and Green MR. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 2003;22:1005."
    },
    {
      "key": "ref22",
      "unstructured": "Di Costanzo F, Sdrobolini A, Carlini P, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P and Ospedaliera S A. Gemcitabine (GEM) Alone or in Combination with 5-FU Continuous Infusion (CI) in the Treatment of Advanced Pancreatic Cancer (APC): a GOIRC Randomized Phase II Trial. Proc Am Soc Clin Oncol 2001;20:612."
    },
    {
      "key": "ref23",
      "unstructured": "Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Stoffregen C and Clemens M. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2003;22:1003."
    },
    {
      "key": "ref24",
      "doi-asserted-by": "crossref",
      "unstructured": "Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR and Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). J Clin Oncol 2004;22:4011.",
      "DOI": "10.1200/jco.2004.22.14_suppl.4011"
    },
    {
      "key": "ref25",
      "unstructured": "Richards DA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Dasse KD, Macdonald K, Gulyas S, Plante M, Copley-Merriman C and Grove W. Randomized, double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994 G) versus placebo plus gemcitabine (P G) in the treatment of patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2002;21:644."
    },
    {
      "key": "ref26",
      "unstructured": "Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, Nomikos D, Ding K, Ptaszynski M, Parulekar W. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. 2005 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to Gastrointestinal Malignancies and Premalignancies; 2005 January 27-29; Hollywood, FL: Abstract 77 ."
    },
    {
      "key": "ref27",
      "doi-asserted-by": "crossref",
      "unstructured": "Stathopoulos G, Aravantinos G, Syrigos K, Kalbakis K, Karvounis N, Papakotoulas P, Boukovinas J, Potamianou A, Polyzos A, Christophillakis C and Georgoulias V. A randomized phase III study of irinotecan/ gemcitabine combination versus gemcitabine in patients with advanced/ metastatic pancreatic cancer. J Clin Oncol 2005;23:4106.",
      "DOI": "10.1200/jco.2005.23.16_suppl.4106"
    },
    {
      "key": "ref28",
      "doi-asserted-by": "crossref",
      "unstructured": "Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K, Weigang-K&ouml;hler K, Stauch M and Oettle H. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:4009.",
      "DOI": "10.1200/jco.2005.23.16_suppl.lba4009"
    },
    {
      "key": "ref29",
      "doi-asserted-by": "crossref",
      "unstructured": "Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, Schueller J, Bernhard J, Dietrich D and Scheithauer W. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005;23:4010.",
      "DOI": "10.1200/jco.2005.23.16_suppl.lba4010"
    },
    {
      "key": "ref30",
      "unstructured": "Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997;24:S7-8-S7-16."
    },
    {
      "key": "ref31",
      "unstructured": "Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-530."
    },
    {
      "key": "ref32",
      "doi-asserted-by": "publisher",
      "DOI": "10.1111/j.1443-9573.2006.00244.x"
    }
  ],
  "container-title": "World Journal of Gastroenterology",
  "original-title": [],
  "language": "en",
  "deposited": {
    "date-parts": [
      [
        2019,
        9,
        5
      ]
    ],
    "date-time": "2019-09-05T11:49:48Z",
    "timestamp": 1567684188000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "http://www.wjgnet.com/1007-9327/full/v12/i43/6973.htm"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2006
      ]
    ]
  },
  "references-count": 32,
  "journal-issue": {
    "issue": "43",
    "published-print": {
      "date-parts": [
        [
          2006
        ]
      ]
    }
  },
  "URL": "http://dx.doi.org/10.3748/wjg.v12.i43.6973",
  "relation": {},
  "ISSN": [
    "1007-9327"
  ],
  "subject": [],
  "container-title-short": "WJG",
  "published": {
    "date-parts": [
      [
        2006
      ]
    ]
  }
}